Restoring Healing at the Cellular Level

MicroCures uses precisely engineered siRNA to temporarily silence FL2 — an intracellular enzyme that restricts cell movement after injury. By removing this biological brake, our technology enables coordinated tissue repair across epithelial, neuronal, and stromal cells.

Pro-Regenerative siRNA Therapies

Traditional regenerative approaches often aim to stimulate healing from the outside—adding growth factors, stem cells, or long-lasting genetic signals. MicroCures takes a different path. Our platform works within the cell, using localized siRNA to restore the natural machinery of repair. The result is a therapeutic approach that is:
  • Intracellular: Acts at the source of impaired healing
  • Temporary: Activity resolves naturally as siRNA degrades
  • Localized: Designed for direct application with minimal systemic exposure
  • Restorative: Supports multiple cell types working together as intended

We’re redefining regenerative medicine by unlocking what biology already knows how to do.

How Healing Breaks Down

Why Injured Cells Can’t Heal

Key players in cell movement1,2:

  • Microtubules — the cell’s internal network — guide how materials move, how cells migrate, and how tissue repairs itself.

  • FL2 — an intracellular enzyme — acts as a natural traffic regulator, controlling how quickly cells and regenerating nerves can move.

Under normal conditions, this system maintains healthy, balanced tissue behavior. But during injury, FL2 becomes overexpressed, excessively restricting the movement of the very cells needed for repair.

As a result:

  • Cell migration slows
  • Wound closure stalls
  • Nerve fibers struggle to regrow
  • Healing becomes incomplete or delayed

Analogy:

Microtubules are the roads cells use to move, and FL2 is the traffic light that controls the flow. During injury, FL2 becomes overactive and turns too many lights red — preventing cells and nerves from reaching the wound.

References:
1. Smart K. & Sharp D.J., Cytoskeleton (2024): FL2 regulates microtubule severing and cell motility.
2. Baker K. et al., JCI Insight (2021): FL2 knockdown enhances axonal growth and tissue repair.

Temporarily Removing the Biological Brake

Our lead siRNA, SiFi2,is engineered to silence FL2 with high specificity, restoring the cell’s ability to move and repair.

1. Localized Delivery

A proprietary lipid nanoparticle (LNP) formulation transports siRNA directly into corneal and epithelial cells after topical application.

2. FL2 Silencing

Inside the cell, the siRNA engages the RNA interference pathway, temporarily reducing FL2 expression and allowing microtubules to stabilize and extend.

3. Coordinated Repair

With FL2 lowered, cells regain motility—closing epithelial defects, supporting nerve regeneration, and helping restore normal tissue architecture.

Analogy:

When FL2 overexpression throws a red traffic light on healing, MCR-231 briefly turns it green, restoring the body’s natural ability to heal.
Platform Advantages

Designed for Precision, Safety & Real-World Use

How Our siRNA Approach Compares

Unlike growth-factor therapies that work at the cell surface, our siRNA acts inside the cell to remove the barrier to repair—enabling broader, more coordinated healing.

Intracellular Mechanism
Temporary, Controlled Activity
Coordinated Repair
Room-Temperature Stable
Patient-Friendly Dosing
MicroCures Pro-Regenerative siRNA (designed to)
  • Works inside the cell (FL2 inhibition)
  • Natural off-switch (siRNA degrades in 48–72 hrs)
  • Supports epithelial + neuronal + stromal repair
  • Yes
  • Every-other-day/ daily
Conventional Pro-Trophic Therapies

Extracellular signaling only

May create prolonged or variable signaling

Single-pathway focused

Requires refrigeration/frozen storage

Frequent or multiple daily dosing

Proof in the Data

Contact Us to Learn More
Across validated preclinical models, FL2 inhibition consistently demonstrates the potential to transform healing outcomes:

Faster Epithelial Closure3

Treated tissues show significantly accelerated wound healing compared to controls.

Increase in Nerve Density3

siRNA-treated corneas regenerate nerve fibers more effectively, restoring sensation and function.

Healthy Tissue Architecture3

Regenerated tissue displays normal structure, reduced scarring, and improved clarity.

References:
1. Smart K. & Sharp D.J., Cytoskeleton (2024): FL2 regulates microtubule severing and cell motility.
2. Baker K. et al., JCI Insight (2021): FL2 knockdown enhances axonal growth and tissue repair.
3. Wang, J., Dey, A., Kramer, A. H., Miao, Y., Liu, J., Baker, L., et al. (2021). A Novel Therapeutic Approach to Corneal Alkaline Burn Model by Targeting Fidgetin-Like 2, a Microtubule Regulator. Translational Vision Science & Technology, 10(1), 17-17.

Discover the Science Behind Our Platform

View Publications
Explore Our Pipeline